TGTX · Tg Therapeutics, Inc. · Earnings Call Transcripts & Audio
Market Cap
$8.25B
Shares
153.07M
Tg Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Tg Therapeutics, Inc. (TGTX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼95.4%
$94,000
−$35.82M
'22 Q3
22-11-10
▼96.5%
$81,000
−$78.47M
'22 Q4
23-02-28
▲287.1%
$7.80M
−$39.23M
'23 Q1
23-05-01
▲2606.1%
$16.07M
−$47.61M
'23 Q2
23-08-01
▲176298.9%
$165.81M
$113.93M
'23 Q3
23-11-01
▲54184%
$43.97M
−$14.42M
'23 Q4
24-02-28
▲713.5%
$63.47M
−$10.71M
'24 Q1
24-05-01
▲357%
$73.47M
$6.88M
'24 Q2
24-08-06
▼49.4%
$83.88M
$3.88M
'24 Q3
24-11-04
▲146%
$108.19M
$23.33M
'24 Q4
25-03-03
▲90.4%
$120.86M
$5.06M
'25 Q1
25-05-05
▲92.1%
$141.15M
$28.19M
'25 Q2
25-08-04
▲92.8%
$161.71M
$390.89M
'25 Q3
25-11-03
▲78%
$192.57M
$23.04M
'25 Q4
26-02-26
▲69.6%
$204.92M
$19.78M
'26 Q1
26-05-06
LATEST
▲70.3%
$240.34M
$7.78M
'26 Q2
26-08-03
Earnings call
FY26 · Q2
2026-08-03
Tg Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
Confident tone
Azercel allogeneic CAR-T program
Capital allocation and share repurchases
Enhanced trial and dosing simplification
Revenue
$240.34M
▲ 70.3% YoY Diluted EPS
$0.05
▼ 70.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Tg Therapeutics, Inc. (TGTX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Tg Therapeutics, Inc. (TGTX) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Tg Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
Confident tone
Operating expenses and gross-to-net dynamics
Long-term franchise outlook and patent runway
Pipeline expansion beyond MS
Revenue
$204.92M
▲ 69.6% YoY Diluted EPS
$0.12
▲ 300% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Tg Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Confident tone
BRIANVI/Breyanvy U.S. sales growth
Multiple sclerosis market positioning
Enhanced dosing Phase III program
Revenue
$192.57M*
▲ 78% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Tg Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript
Confident tone
BRIUMVI commercial performance
Pipeline expansion (ENHANCE and subcu)
2026 outlook and guidance
Revenue
$161.71M
▲ 92.8% YoY Diluted EPS
$2.43
▲ 12050% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Tg Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
Confident tone
Sub-Q Briumvy development
Net sales and guidance
Growth-to-net and pricing dynamics
Revenue
$141.15M
▲ 92.1% YoY Diluted EPS
$0.17
▲ 325% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-05
Tg Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript
Confident tone
BRIUMVI commercial launch momentum
Raised 2025 revenue guidance
Competitive positioning vs other anti-CD20s
Revenue
$120.86M
▲ 90.4% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Tg Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript
Confident tone
BRIUMVI Commercial Performance
ENHANCE Study / Patient Experience Improvements
Subcutaneous BRIUMVI Development
Revenue
$108.19M*
▲ 146% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
Tg Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript
Confident tone
BRIUMVI commercial launch and sales growth
Pipeline expansion (azer-cel CAR-T, non-MS indications)
Capital allocation and share buybacks
Revenue
$83.88M
▼ 49.4% YoY Diluted EPS
$0.02
▼ 97.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Tg Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call Transcript
Confident tone
BRIUMVI Commercial Launch and Sales
Azer-cel CAR-T for Autoimmune Diseases
ENHANCE Switch Study
Revenue
$73.47M
▲ 357% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Tg Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
Confident tone
Briumvi U.S. commercial performance
VA contract and market access
Azer-cel CAR T partnership and pipeline expansion
Revenue
$63.47M
▲ 713.5% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Tg Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript
Confident tone
BRIUMVI commercial launch and revenue ramp
Pipeline expansion / azer-cel partnership
BRIUMVI lifecycle management (subcutaneous, enhanced dosing)
Revenue
$43.97M*
▲ 54184% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Tg Therapeutics, Inc. (TGTX) Q3 2023 Earnings Call Transcript
Revenue
$165.81M
▲ 176298.9% YoY Diluted EPS
$0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Tg Therapeutics, Inc. (TGTX) Q2 2023 Earnings Call Transcript
Revenue
$16.07M
▲ 2606.1% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
Tg Therapeutics, Inc. (TGTX) Q1 2023 Earnings Call Transcript
Revenue
$7.80M
▲ 287.1% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Tg Therapeutics, Inc. (TGTX) Q4 2022 Earnings Call Transcript
Revenue
$81,000*
▼ 96.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Tg Therapeutics, Inc. (TGTX) Q3 2022 Earnings Call Transcript
Revenue
$94,000
▼ 95.4% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Tg Therapeutics, Inc. (TGTX) Q2 2022 Earnings Call Transcript
Revenue
$594,000
▼ 61.6% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Tg Therapeutics, Inc. (TGTX) Q4 2021 Earnings Call Transcript
Revenue
$2.32M*
▲ 6007.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Tg Therapeutics, Inc. (TGTX) Q3 2021 Earnings Call Transcript
Revenue
$2.03M
▲ 5242.1% YoY Diluted EPS
$-0.65
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Tg Therapeutics, Inc. (TGTX) Q2 2021 Earnings Call Transcript
Revenue
$1.54M
▲ 3965.8% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Tg Therapeutics, Inc. (TGTX) Q1 2021 Earnings Call Transcript
Revenue
$793,000
▲ 1986.8% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
Tg Therapeutics, Inc. (TGTX) Q4 2020 Earnings Call Transcript
Revenue
$38,000*
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Tg Therapeutics, Inc. (TGTX) Q3 2020 Earnings Call
Revenue
$38,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Tg Therapeutics, Inc. (TGTX) Q2 2020 Earnings Call Transcript
Revenue
$38,000
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-03
Tg Therapeutics, Inc. (TGTX) Q4 2019 Earnings Call
Revenue
$38,000*
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1001316
CUSIP
88322Q108
13F (30d)
14 filings
13 filers
Visit website
Investor relations